Trial · NCT03250273
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) | Arm A - Cholangiocarcinoma | 0 | Participants | ||
| Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) | ARM B - Pancreatic Cancer | 3 | Participants | ||
| Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE) | Arm A - Cholangiocarcinoma | 5 | Participants | ||
| Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE) | ARM B - Pancreatic Cancer | 19 | Participants | ||
| Overall Survival (OS) | Arm A - Cholangiocarcinoma | 6.378 | 95% Confidence Interval 3.748 to NA | months | |
| Overall Survival (OS) | ARM B - Pancreatic Cancer | 2.729 | 95% Confidence Interval 1.84 to 5.62 | months | |
| Overall Survival (OS) at 6 Months | Arm A - Cholangiocarcinoma | 0.538 | 95% Confidence Interval 0.326 to 0.891 | proportion of participants | |
| Overall Survival (OS) at 6 Months | ARM B - Pancreatic Cancer | 0.277 | 95% Confidence Interval 0.153 to 0.498 | proportion of participants | |
| Overall Survival (OS) at 12 Months | Arm A - Cholangiocarcinoma | 0.308 | 95% Confidence Interval 0.136 to 0.695 | proportion of participants | |
| Overall Survival (OS) at 12 Months | ARM B - Pancreatic Cancer | 0.138 | 95% Confidence Interval 0.056 to 0.343 | proportion of participants | |
| Overall Survival (OS) at 24 Months | Arm A - Cholangiocarcinoma | 0.077 | 95% Confidence Interval 0.012 to 0.506 | proportion of participants | |
| Overall Survival (OS) at 24 Months | ARM B - Pancreatic Cancer | 0.035 | 95% Confidence Interval 0.005 to 0.237 | proportion of participants | |
| Overall Survival (OS) at 36 Months | Arm A - Cholangiocarcinoma | 0.077 | 95% Confidence Interval 0.012 to 0.506 | proportion of participants | |
| Overall Survival (OS) at 36 Months | ARM B - Pancreatic Cancer | 0.035 | 95% Confidence Interval 0.005 to 0.237 | proportion of participants | |
| Duration of Response (DOR) | ARM B - Pancreatic Cancer | 10.2 | Full Range 3.7 to 17.9 | months | |
| Progression Free Survival (PFS) at 6 Months | Arm A - Cholangiocarcinoma | 0 | 95% Confidence Interval NA to NA | proportion of participants | |
| Progression Free Survival (PFS) at 6 Months | ARM B - Pancreatic Cancer | 0.067 | 95% Confidence Interval 0.017 to 0.254 | proportion of participants | |
| Progression Free Survival (PFS) at 12 Months | Arm A - Cholangiocarcinoma | 0 | 95% Confidence Interval NA to NA | proportion of participants | |
| Progression Free Survival (PFS) at 12 Months | ARM B - Pancreatic Cancer | 0.067 | 95% Confidence Interval 0.017 to 0.254 | proportion of participants | |
| Progression Free Survival (PFS) at 24 Months | Arm A - Cholangiocarcinoma | 0 | 95% Confidence Interval NA to NA | proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03250273/results